Ligand-inducible, prostate stem cell antigen (PSCA)-directed GoCAR-T™ cells in advanced solid tumors: Preliminary results from a dose escalation study

Abstract

Background: PSCA, a cell surface protein, is upregulated in many solid tumors & correlates with disease stage. BPX601 is an autologous, T-cell product engineered to contain a PSCA-CD3n CAR plus the small molecule rimiducid (Rim)-inducible MyD88/ CD40 costimulatory domain. BPX601 is optimized for antigen-directed & independent T cell activation, proliferation & persistence, potentially enhancing efficacy in solid tumors versus traditional CARs. This first-in-human study assesses the safety, biological & clinical activity of BPX601 plus Rim in select PSCA-positive cancers. Methods: NCT02744287 is a 2-part, open-label trial. Part 1 is an ongoing 3 þ 3 cell dose escalation to identify the recommended BPX601 cell dose (Day 0) given in combination with a fixed, single Rim dose (0.4 mg/kg; Day 7). Eligibility criteria include previously treated metastatic pancreatic cancer (mPDAC) with measurable disease & positive PSCA expression. Results: Patients received only cyclophosphamide (CTX) for lymphodepletion (LD) within 3 days before BPX601 infusion. Nine adults have been treated across 3 cell dose levels (cells/kg): 1.25x10 6 (cells only), 1.25x10 6 þRim, 2.5x10 6 þRim. All had mPDAC with 2 prior therapies. Common AEs were fatigue & nausea. No DLTs, related SAEs, neurotoxicity or CRS events were reported. Rapid cell engraftment by Day 4 was observed in all patients. No evidence of LD with CTX was seen. Of 6 patients that received Rim: 2 had cell expansion 10-to 20-fold within 7 days; 2 had cell persistence >3 weeks; all had elevated serum cytokines (IP-10, TNFa) correlated with cell expansion. Best response after 1 scan was 4 SD 8 weeks with 2 minor responses (not confirmed; 1 patient had matched CA19-9 decrease) & 2 PD. Disease control without new therapy was 16 & >11 weeks (ongoing) in 1 & 3 patients, respectively. Conclusions: BPX601 with single-dose Rim was well-tolerated & resulted in enhanced T cell expansion & prolonged persistence in some patients despite lack of LD. Evidence of clinical benefit in this heavily pretreated mPDAC population was seen. Part 2 is planned to open soon & will include CTX/fludarabine LD to maximize engraftment as well as gastric & prostate cancers. Clinical trial identification: NCT02744287. Legal entity responsible for the study: Bellicum Pharmaceuticals. Funding: Bellicum Pharmaceuticals.

Immunotherapy in non-melanoma skin cancer: updates and new perspectives

“…An independent central review committee performed tumor response assessment every 8 weeks to determine the overall response rate. The results showed a partial response rate of 50%, a durable disease control rate of 65.4%, and a quick onset of the clinical response 35…”

“…The study included patients with locally advanced and metastatic CSCC. In the phase I study, cemiplimab was administered every 2 weeks for up to 48 weeks in 26 patients (10 with metastatic disease and 16 with locally advanced disease) 35. Patients’ characteristics included a median age over 70 years, comorbidities, an aging immune system, and an ECOG performance status score of 0 or 1.…”

Monoclonal antibodies in cervical malignancy-related HPV

“…In this regard, cemiplimab was approved in 2018 in the United States for the treatment of patients with metastatic or advanced SCC who did not respond to radiation therapy or surgery. In a phase II clinical trial (NCT02760498) studying cemiplimab ( 81 ), the patients showed a 47% immune response after 1.9 months ( 80 ). It is noteworthy that cemiplimab entered directly into the phase III clinical trials following the results obtained in phase I and II studies ( 82 ).…”